 |
|
|
| |
Real-world Treatment Experience of Single-tablet Dolutegravir/Lamivudine in those Naïve to Treatment
with Baseline Viral Loads ≥100,000 copies/mL the United States
|
| |
| |
IDWeek 2022; October 19-23, 2022; Virtual and Washington, DC
P Benson1, C Donovan2, G Harper3, D Merrill2, K Mycock3, A Oglesby,2 J Patarroyo2, A Metzner2
1Be Well Medical Center, Berkley, MI, USA; 2ViiV Healthcare, Durham, NC, USA; 3Adelphi Real World, Bollington, Cheshire, UK
|
| |
|
|
|
|
|
